Pharmaceutical Technology

NOVEMBER 25, 2022

CK Life Sciences vice-president and chief scientific officer Dr Melvin Toh said: “The cooperation with XtalPi will apply XtalPi’s AI algorithm, molecular modelling and automated experiments to speed up the R&D process, improve the success rate, and increase the efficacy of tumour vaccines.”.

Vaccines 98

Vaccines Process Improvement Immunization Compounding 98

Impact Pharmaceutical Services

SEPTEMBER 15, 2023

Structure-based drug design has evolved, facilitating the exploration of novel chemical probes and lead compound potency, and molecular docking utilizes target structures to predict interactions and offers simplicity and speed. Both processes are evolving to enhance product development and output.

Documentation 59

Documentation Process Improvement Compounding 59

ISPE

OCTOBER 27, 2022

Broad pipelines require facilities to be designed with a large degree of flexibility to support anything from mild reaction conditions to the use of potent or highly biologically active compounds. Cone-bottom reaction vessels can provide the turndown required to process a variety of scales and handle different reactions.

Process Improvement 98

Process Improvement Packaging Dosage Compounding 98

ISPE

SEPTEMBER 11, 2023

Examples include platforms as small as autonomous units placed within a facility and mobile production trailers for compounding to platforms as large as a prefabricated, self-contained GMP facility. 3 , 27 Advantages POD increases manufacturing flexibility, speed, and consistency. This can simplify future scale-up and technology transfer.

Health and Personal Care Stores 52

Health and Personal Care Stores Vaccines Packaging Documentation 52

ISPE

MARCH 29, 2023

The list of potential CQAs can be modified when the formulation and manufacturing process are selected and as product knowledge and process understanding increase.” The initial risk assessment is based on information on the target compound as well as prior knowledge and experience from other products with similar characteristics.

Documentation 52

Documentation Dosage Packaging Communication 52

ISPE

MARCH 29, 2023

The list of potential CQAs can be modified when the formulation and manufacturing process are selected and as product knowledge and process understanding increase.” The initial risk assessment is based on information on the target compound as well as prior knowledge and experience from other products with similar characteristics.

Documentation 52

Documentation Dosage Packaging Communication 52

ISPE

AUGUST 30, 2022

With shortages, regulatory complexity is compounded due to differences in submission and data requirements from various regulatory agencies. Burke, PhD. 1 September 2022. A reliable supply of raw materials is critical to maintain a robust supply chain to serve patients globally.

Documentation 52

Documentation FDA Packaging Communication 52